Late Breaking Data at ADA 2006 Shows Amylin-Leptin Co-Administration Reduces Body Weight and Body Fat in Animal Studies
June 10 2006 - 11:00AM
PR Newswire (US)
WASHINGTON, June 10 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced study results
showing that co-administration of two neurohormones known to have a
role in body weight control, amylin (produced by beta cells in the
pancreas) and leptin (produced by fat cells), resulted in
sustained, fat-specific weight loss in a leptin-resistant animal
model of obesity. These findings were presented at the 66th Annual
Scientific Sessions of the American Diabetes Association (ADA) in
Washington, D.C in a poster titled "Leptin Responsivity Restored in
Leptin-Resistant Diet-Induced Obese Rats: Synergistic Actions of
Amylin and Leptin for Reduction in Body Weight and Fat." "These
findings provide preclinical proof of concept that amylin can
restore leptin responsiveness in obese leptin-resistant animals.
The study further demonstrates the potential to treat obesity with
a combination therapy that employs multiple weight-regulating
neurohormones," said Alain Baron, Senior Vice President, Research,
at Amylin Pharmaceuticals. "A clinical study to further
substantiate these results is planned to start later this year." In
leptin-resistant, diet-induced obese rats, co-administration of
amylin and leptin resulted in a decrease in food intake and body
weight greater than that seen with either hormone. The amylin plus
leptin combination also increased fat oxidation (fat stores used
up) and prevented the fall in energy expenditure (calories used up)
that is usually expected with weight loss. Weight loss occurred due
to decreased fat mass, while lean tissue was preserved. The full
abstract is available online at
http://scientificsessions.diabetes.org/ by searching for abstract
number 52-LB. "We will pursue the development of novel obesity
therapies with the same scientific rigor we brought to the
development of our first-in-class diabetes drugs BYETTA(R) and
SYMLIN(R)," said Ginger L. Graham, Amylin's Chief Executive
Officer. "We see great potential in examining how integrated
neurohormonal pathways can be used to treat obesity and other
metabolic disorders. This approach is in line with our research
philosophy that hormones with multiple actions may have tremendous
potential, whether used alone or as part of a combination therapy."
Amylin acquired exclusive rights to the leptin molecular franchise
and on- going clinical program earlier this year. About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first-in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin's research and development activities leverage
the company's expertise in metabolism to develop promising
therapies to treat diabetes, obesity and cardiovascular disease.
Amylin is located in San Diego, California with over 1200 employees
nationwide. Further information on Amylin Pharmaceuticals is
available at http://www.amylin.com/. This press release contains
forward-looking statements about Amylin. The company's actual
results could differ materially from those discussed in this press
release due to a number of risks and uncertainties, including that
clinical trials will replicate previous preclinical study or
clinical trial results; that clinical trials will commence or
conclude when planned; risks that Amylin's compounds will not
receive regulatory approval and in the FDA's approval process
generally; risks that Amylin's research approach will be able to
develop product candidates or result in approved products; and
risks and uncertainties inherent in the drug discovery and
development process. These and additional risks and uncertainties
are described more fully in the Company's recently filed Form 10-Q.
Amylin disclaims any obligation update these forward-looking
statements. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Lorie
Fiber of Edelman, +1-310-383-6583, for Amylin Pharmaceuticals,
Inc.; or Alice Bahner of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200, ext. 7272 Web site: http://www.amylin.com/
http://scientificsessions.diabetes.org/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024